Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Scientists have developed an experimental mRNA vaccine that, when combined with existing immunotherapy drugs, could 'teach' the immune system to recog ...

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...

The researchers found that mRNA-based COVID-19 vaccines could potentially help patients whose tumors don’t respond well to ...

The COVID-19 mRNA-based vaccines that saved 2.5 million lives globally during the pandemic could help spark the immune system ...

People with advanced lung or skin cancer who were taking certain immunotherapy drugs lived substantially longer if they also ...

Researchers found that COVID-19 mRNA vaccines significantly increased survival in lung and skin cancer patients undergoing ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

The Senate Homeland Security and Governmental Affairs Committee held a powerful hearing on vaccine injury testimonies. Among ...

University of Florida researchers found that advanced lung and skin cancer patients lived “significantly longer” after ...